Mylan (MYL) Tops Q3 EPS by 5c; Sees FY15 EPS at High End of Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business
October 30, 2015 7:15 AM EDTHERTFORDSHIRE, England and PITTSBURGH, Oct. 30, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL), a leading global pharmaceutical company, today announced the appointment of Ranjan Ray Chaudhuri to serve as global commercial lead of the company's over-the-counter (OTC) business. Chaudhuri will report to Rajiv Malik, president of Mylan.
Chaudhuri joins Mylan from GlaxoSmithKline (GSK) Consumer Healthcare, where he served for nearly three decades, and brings to Mylan a world of experience. During his time at GSK, Chaudhuri was responsible for the company's global smoking reduction and cessation category, which included NiQuitin® and other... More
Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted EPS Increases 23% to $1.43
October 30, 2015 7:00 AM EDTHERTFORDSHIRE, ENGLAND and PITTSBURGH, Oct. 30, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced its financial results for the quarter ended September 30, 2015.
Third Quarter 2015 Highlights
Adjusted total revenues of $2.71 billion, up 36% on a constant currency basis versus the prior year period. GAAP total revenues of $2.70 billion. Excluding the impact of the acquisition of Abbott's non-U.S. developed markets specialty and branded generics business ("EPD Business"), adjusted total revenues increased 14% on a constant currency basis, reflecting the continued strength in our legacy business. Foreign currency exchange rates... MoreU.S. District Court Denies Perrigo's Motion for Preliminary Injunction Related to Certain Mylan Disclosures
October 30, 2015 6:45 AM EDTHERTFORDSHIRE, England and PITTSBURGH, Oct. 30, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that the U.S. District Court for the Southern District of New York has denied the motion by Perrigo Company plc (NYSE: PRGO; TASE) for a preliminary injunction concerning Mylan's proposed acquisition of Perrigo, ruling that Mylan had provided adequate public disclosures regarding the synergies expected to be achieved from the combination.
The court also ruled that Mylan's disclosures regarding its intention to de-list Perrigo from the NYSE and the TASE as soon as practicable following... More
Mylan Confirms Availability of EpiPen® (epinephrine injection) Auto-Injector for U.S. Patients Affected by Sanofi's Auvi-Q® (epinephrine injection, USP) Recall
October 29, 2015 1:23 PM EDTHERTFORDSHIRE, England and PITTSBURGH, Oct. 29, 2015 /PRNewswire/ -- Mylan Specialty, a division of Mylan N.V. (Nasdaq: MYL) which markets and distributes EpiPen® (epinephrine injection) Auto-Injector, today commented on the voluntary nationwide recall of Sanofi's Auvi-Q® (epinephrine injection, USP) auto-injector. Mylan confirms that EpiPen® and EpiPen Jr® (epinephrine injection) Auto-Injectors are not affected by the Auvi-Q® recall, and the company has sufficient supply of EpiPen® Auto-Injector to meet any anticipated demand.
Yesterday, Sanofi announced the recall of all Auvi-Q® auto-injectors currently on the market, including the 0.15 mg and 0.3... More
Tel Aviv District Court Rules in Favor of Mylan Listing on Tel Aviv Stock Exchange
October 28, 2015 3:11 PM EDTHERTFORDSHIRE, England and PITTSBURGH, Oct. 28, 2015 /PRNewswire/ --Â Mylan N.V. (NASDAQ: MYL) today announced that the Tel Aviv District Court denied an attempt by Perrigo Company plc (NYSE: PRGO; TASE) to prevent Mylan from listing its shares on the Tel Aviv Stock Exchange (TASE).
Mylan's Executive Chairman Robert J. Coury commented, "We are very pleased by the Court's ruling, clearing the way for the TASE to approve our listing and for Perrigo's Israeli shareholders to participate in our highly compelling offer, which would provide them with immediate and significant... More
